These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 34743497)

  • 1. [Advances in the Treatment of RET Fusion-positive Advanced Non-small Cell Lung Cancer].
    Gao Q; Su J; Xiao F; Lin X; Yang J
    Zhongguo Fei Ai Za Zhi; 2021 Dec; 24(12):853-861. PubMed ID: 34743497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
    Sun F; McCoach CE
    Curr Treat Options Oncol; 2021 Jun; 22(8):72. PubMed ID: 34165651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
    Lin JJ; Liu SV; McCoach CE; Zhu VW; Tan AC; Yoda S; Peterson J; Do A; Prutisto-Chang K; Dagogo-Jack I; Sequist LV; Wirth LJ; Lennerz JK; Hata AN; Mino-Kenudson M; Nardi V; Ou SI; Tan DS; Gainor JF
    Ann Oncol; 2020 Dec; 31(12):1725-1733. PubMed ID: 33007380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pralsetinib: A Review in Advanced RET Fusion-Positive NSCLC.
    Syed YY
    Drugs; 2022 May; 82(7):811-816. PubMed ID: 35587858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes.
    Rocco D; Sapio L; Della Gravara L; Naviglio S; Gridelli C
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
    Solomon BJ; Tan L; Lin JJ; Wong SQ; Hollizeck S; Ebata K; Tuch BB; Yoda S; Gainor JF; Sequist LV; Oxnard GR; Gautschi O; Drilon A; Subbiah V; Khoo C; Zhu EY; Nguyen M; Henry D; Condroski KR; Kolakowski GR; Gomez E; Ballard J; Metcalf AT; Blake JF; Dawson SJ; Blosser W; Stancato LF; Brandhuber BJ; Andrews S; Robinson BG; Rothenberg SM
    J Thorac Oncol; 2020 Apr; 15(4):541-549. PubMed ID: 31988000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selpercatinib in RET-fusion positive metastatic non-small cell lung cancer: achievements and gray areas.
    Belluomini L; Avancini A; Pasqualin L; Insolda J; Sposito M; Menis J; Tregnago D; Trestini I; Ferrara MG; Bria E; Milella M; Pilotto S
    Expert Rev Anticancer Ther; 2022 Aug; 22(8):785-794. PubMed ID: 35726802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress and challenges in RET-targeted cancer therapy.
    Hu X; Khatri U; Shen T; Wu J
    Front Med; 2023 Apr; 17(2):207-219. PubMed ID: 37131086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
    Gainor JF; Curigliano G; Kim DW; Lee DH; Besse B; Baik CS; Doebele RC; Cassier PA; Lopes G; Tan DSW; Garralda E; Paz-Ares LG; Cho BC; Gadgeel SM; Thomas M; Liu SV; Taylor MH; Mansfield AS; Zhu VW; Clifford C; Zhang H; Palmer M; Green J; Turner CD; Subbiah V
    Lancet Oncol; 2021 Jul; 22(7):959-969. PubMed ID: 34118197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer.
    Wang C; Zhang Z; Sun Y; Wang S; Wu M; Ou Q; Xu Y; Chen Z; Shao Y; Liu H; Hou P
    J Transl Med; 2022 Sep; 20(1):390. PubMed ID: 36059009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
    Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
    J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.
    Griesinger F; Curigliano G; Thomas M; Subbiah V; Baik CS; Tan DSW; Lee DH; Misch D; Garralda E; Kim DW; van der Wekken AJ; Gainor JF; Paz-Ares L; Liu SV; Kalemkerian GP; Houvras Y; Bowles DW; Mansfield AS; Lin JJ; Smoljanovic V; Rahman A; Kong S; Zalutskaya A; Louie-Gao M; Boral AL; Mazières J
    Ann Oncol; 2022 Nov; 33(11):1168-1178. PubMed ID: 35973665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
    Subbiah V; Shen T; Terzyan SS; Liu X; Hu X; Patel KP; Hu M; Cabanillas M; Behrang A; Meric-Bernstam F; Vo PTT; Mooers BHM; Wu J
    Ann Oncol; 2021 Feb; 32(2):261-268. PubMed ID: 33161056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selpercatinib: A Review in Advanced RET Fusion-Positive NSCLC.
    Nie T; Syed YY
    Target Oncol; 2023 Jan; 18(1):169-176. PubMed ID: 36422787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape.
    Novello S; Califano R; Reinmuth N; Tamma A; Puri T
    Oncologist; 2023 May; 28(5):402-413. PubMed ID: 36821595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP).
    Passaro A; Russo GL; Passiglia F; D'Arcangelo M; Sbrana A; Russano M; Bonanno L; Giusti R; Metro G; Bertolini F; Grisanti S; Carta A; Cecere F; Montrone M; Massa G; Perrone F; Simionato F; Guaitoli G; Scotti V; Genova C; Lugini A; Bonomi L; Attili I; de Marinis F
    Lung Cancer; 2022 Dec; 174():118-124. PubMed ID: 36379124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting RET alterations in non-small cell lung cancer.
    Nishikawa G; Klein MA
    Curr Probl Cancer; 2024 Apr; 49():101074. PubMed ID: 38494387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
    Rosen EY; Johnson ML; Clifford SE; Somwar R; Kherani JF; Son J; Bertram AA; Davare MA; Gladstone E; Ivanova EV; Henry DN; Kelley EM; Lin M; Milan MSD; Nair BC; Olek EA; Scanlon JE; Vojnic M; Ebata K; Hechtman JF; Li BT; Sholl LM; Taylor BS; Ladanyi M; Jänne PA; Rothenberg SM; Drilon A; Oxnard GR
    Clin Cancer Res; 2021 Jan; 27(1):34-42. PubMed ID: 33082208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chinese expert consensus on the diagnosis and treatment of advanced RET fusion-positive non-small cell lung cancer (2023 edition)].
    ; ;
    Zhonghua Zhong Liu Za Zhi; 2023 Dec; 45(12):991-1002. PubMed ID: 38110308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges.
    Servetto A; Esposito D; Ferrara R; Signorelli D; Belli S; Napolitano F; Santaniello A; Ciciola P; Formisano L; Bianco R
    Biochim Biophys Acta Rev Cancer; 2022 Nov; 1877(6):188810. PubMed ID: 36202311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.